Subsequently, another study to mitigate neratinib-induced diarrhea called CONTROL study, [21] was designed to prospectively evaluate multiple strategies for managing neratinib-induced diarrhea, including gradual neratinib dose escalation, concomitantly with oral doses of loperamide, budesonide, and/or colestipol, in different arms of HER2-positive breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.